These HER-2/neu peptides have been demonstrated to bind to HLA-A2.1 molecules with high affinities (Fisk et al 1995; Rongcun et al, 1999), thereby eliciting CTL activity among tumour-associated lymphocytes in patients with breast and ovarian cancer (Fisk et al, 1995; Rongcun et al, 1999; Baxevanis et al, 2002). This evidence concerns the gene ERBB2 and ovarian cancer.